---
title: "Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277696391.md"
description: "Abbisko Cayman Limited has announced the first patient dosing in a Phase I/II trial of ABSK141, a small-molecule inhibitor targeting KRAS G12D mutations in advanced solid tumors. This milestone, cleared by the U.S. FDA and China’s NMPA, positions Abbisko to compete in KRAS-targeted therapy, an area of significant industry focus. Preclinical data suggest ABSK141 may provide best-in-class oral bioavailability and anti-tumor activity. The current analyst rating for Abbisko Cayman Limited (HK:2256) is a Hold with a price target of HK$13.00."
datetime: "2026-03-04T00:07:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277696391.md)
  - [en](https://longbridge.com/en/news/277696391.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277696391.md)
---

# Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Abbisko Cayman Limited ( (HK:2256) ) has provided an announcement.

Abbisko Therapeutics, the oncology-focused subsidiary of Abbisko Cayman Limited, has advanced its pipeline with the first patient dosing in a Phase I/II trial of ABSK141, an oral, highly potent and selective small-molecule inhibitor targeting KRAS G12D mutations in advanced solid tumors. KRAS G12D, a predominant oncogenic mutation in pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer, has long been considered an undruggable target, with no approved therapies globally.

The study, cleared by both the U.S. FDA and China’s NMPA in December 2025, marks a key milestone in Abbisko’s effort to establish a foothold in KRAS-targeted therapy, an area of intense industry focus. Preclinical data suggest ABSK141 may offer best-in-class oral bioavailability and strong anti-tumor activity, positioning the program as a potentially transformative option for patients and reinforcing Abbisko’s ambitions to compete internationally in next-generation cancer treatments, though clinical and regulatory outcomes remain uncertain.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

**More about Abbisko Cayman Limited**

Abbisko Cayman Limited, through its Shanghai-based subsidiary Abbisko Therapeutics, is an oncology-focused biopharmaceutical group dedicated to discovering and developing innovative precision oncology and immuno-oncology medicines for unmet medical needs in China and globally. Founded in 2016 by veterans from multinational pharmaceutical companies, it has built an extensive pipeline of novel targeted therapies, with a growing emphasis on small-molecule inhibitors for difficult cancer drivers.

**Average Trading Volume:** 1,493,495

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$8.08B

Learn more about 2256 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02256.HK](https://longbridge.com/en/quote/02256.HK.md)

## Related News & Research

- [BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models](https://longbridge.com/en/news/286973840.md)
- [Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem](https://longbridge.com/en/news/287218916.md)
- [08:03 ETNCCN reafirma su compromiso con los recursos para el manejo del malestar relacionado con el cáncer](https://longbridge.com/en/news/287060831.md)
- [Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug](https://longbridge.com/en/news/286266501.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)